CRISPR Therapeutics (CRSP) free cash flow

Free cash flow · fiscal 2025
-$370.93M

CRISPR Therapeutics (CRSP) generated free cash flow of -$370.93M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$144.68M. Figures as of 18 Nov 2026, 12:21 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$370.93M
Highest on record
$457.27Mfiscal 2021
Lowest on record
-$532.93Mfiscal 2022
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CRISPR Therapeutics free cash flow, in more detail

Across the 11 fiscal years on record (2015–2025), the highest was $457.27M in fiscal 2021 and the lowest -$532.93M in fiscal 2022.

History · 11 fiscal years

Free cash flow by fiscal year

CRISPR Therapeutics free cash flow, year by year

CRISPR Therapeutics (CRSP) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$370.93M—
2024-$144.68M—
2023-$272.35M—
2022-$532.93M 216.5% down
2021$457.27M—
2020-$256.72M 613.5% down
2019$49.99M—
2018-$99.01M—
2017-$77.91M—
2016-$55.88M 195.9% down
2015$58.27M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of CRISPR Therapeutics and comparable companies
CompanyFree cash flowFiscal year
MiniMed Group MMED-$420.00M2026
Adaptive Biotechnologies ADPT-$48.95M2025
Heartflow HTFL-$59.05M2025
CRISPR Therapeutics CRSP-$370.93M2025
Travere Therapeutics TVTX-$20.37M2025
Option Care Health OPCH$217.14M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics free cash flow: questions and answers

What is CRISPR Therapeutics's free cash flow?

CRISPR Therapeutics (CRSP) generated free cash flow of -$370.93M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$144.68M.

What are the highest and lowest free cash flow figures on record for CRISPR Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was $457.27M in fiscal 2021 and the lowest -$532.93M in fiscal 2022.

How is CRISPR Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For CRISPR Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/CRSP/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.